Scaffold-based delivery of nucleic acid therapeutics for enhanced bone and cartilage repair

dc.check.date2020-05-01
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorKelly, Domhnall C.
dc.contributor.authorRaftery, Rosanne M.
dc.contributor.authorCurtin, Caroline M.
dc.contributor.authorO'Driscoll, Caitríona M.
dc.contributor.authorO'Brien, Fergal J.
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderEuropean Regional Development Funden
dc.contributor.funderIrish Research Councilen
dc.date.accessioned2019-08-29T08:58:26Z
dc.date.available2019-08-29T08:58:26Z
dc.date.issued2019-05-01
dc.date.updated2019-08-29T08:50:42Z
dc.description.abstractRecent advances in tissue engineering have made progress toward the development of biomaterials capable of the delivery of growth factors, such as bone morphogenetic proteins, in order to promote enhanced tissue repair. However, controlling the release of these growth factors on demand and within the desired localized area is a significant challenge and the associated high costs and side effects of uncontrolled delivery have proven increasingly problematic in clinical orthopedics. Gene therapy may be a valuable tool to avoid the limitations of local delivery of growth factors. Following a series of setbacks in the 1990s, the field of gene therapy is now seeing improvements in safety and efficacy resulting in substantial clinical progress and a resurgence in confidence. Biomaterial scaffold‐mediated gene therapy provides a template for cell infiltration and tissue formation while promoting transfection of cells to engineer therapeutic proteins in a sustained but ultimately transient fashion. Additionally, scaffold‐mediated delivery of RNA‐based therapeutics can silence specific genes associated with orthopedic pathological states. This review will provide an overview of the current state‐of‐the‐art in the field of gene‐activated scaffolds and their use within orthopedic tissue engineering applications.en
dc.description.sponsorshipIrish Research Council (Grant Number: GOIPG/2018/37)en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationKelly, D. C., Raftery, R. M., Curtin, C. M., O’Driscoll, C. M. and O’Brien, F. J. (2019) 'Scaffold-Based Delivery of Nucleic Acid Therapeutics for Enhanced Bone and Cartilage Repair', Journal of Orthopaedic Research, 37(8), pp. 1671-1680. doi: 10.1002/jor.24321en
dc.identifier.doi10.1002/jor.24321en
dc.identifier.endpage1680en
dc.identifier.issn0736-0266
dc.identifier.issued8en
dc.identifier.journaltitleJournal of Orthopaedic Researchen
dc.identifier.startpage1671en
dc.identifier.urihttps://hdl.handle.net/10468/8408
dc.identifier.volume37en
dc.language.isoenen
dc.publisherWileyen
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/en
dc.relation.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/jor.24321
dc.rights© 2019 Orthopaedic Research Society. Published by Wiley Periodicals. This is the peer reviewed version of the following article: (2019), Scaffold‐Based Delivery of Nucleic Acid Therapeutics for Enhanced Bone and Cartilage Repair. J Orthop Res, 37: 1671-1680, which has been published in final form at https://doi.org/10.1002/jor.24321. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en
dc.subjectBiomaterialsen
dc.subjectBoneen
dc.subjectCartilageen
dc.subjectGene therapyen
dc.subjectOrthopedic tissue engineering and repairen
dc.titleScaffold-based delivery of nucleic acid therapeutics for enhanced bone and cartilage repairen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
10004.pdf
Size:
681.84 KB
Format:
Adobe Portable Document Format
Description:
Accepted version
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description: